📣 VC round data is live. Check it out!

Ventyx Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Ventyx Biosciences and similar public comparables like Guizhou Sanli, Inventiva, Absci, Collegium Pharmaceutical and more.

Ventyx Biosciences Overview

About Ventyx Biosciences

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.


Founded

2018

HQ

United States

Employees

82

Financials (FY)

Revenue: -
Net Income: -

EV

$822M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Ventyx Biosciences Stock Performance

Ventyx Biosciences has current market cap of $1B, and enterprise value of $822M.

Market Cap Evolution


Ventyx Biosciences' stock price is $14.00.

Ventyx Biosciences share price increased by 554.9% in the last year.

See more trading valuation data for Ventyx Biosciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$822M$1B0.0%--554.9%-

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Ventyx Biosciences Valuation Multiples

Ventyx Biosciences Financial Valuation Multiples

As of June 3, 2026, Ventyx Biosciences has market cap of $1B and EV of $822M.

LTMLast FY202320242025202620272028

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Ventyx Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Valuation Multiples Across 230+ Verticals

Ventyx Biosciences Competitors

Ventyx Biosciences competitors include Guizhou Sanli, Inventiva, Absci, Collegium Pharmaceutical, CStone Pharmaceuticals, Corvus Pharma, China TCM, ACROBiosystems, Xeris Biopharma and Strides Pharma.

Most Ventyx Biosciences public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Guizhou Sanli4.1x-46.1x-
Inventiva156.9x172.2x(5.1x)(5.1x)
Absci309.7x190.3x(8.4x)(7.7x)
Collegium Pharmaceutical1.8x1.7x3.0x2.9x
CStone Pharmaceuticals23.6x18.2x(17.4x)(18.6x)
Corvus Pharma-(8854.1x)(17.4x)(14.8x)
China TCM0.3x0.3x4.4x3.2x
ACROBiosystems6.4x5.8x22.5x20.9x

This data is available for Pro users. Sign up to see all Ventyx Biosciences competitors and their valuation data.

Start Free Trial

Ventyx Biosciences VC Funding History

Before going public, Ventyx Biosciences raised $165M in total equity funding, across 2 rounds.


Ventyx Biosciences Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Sep-21Series BCormorant Asset Management; Farallon Capital Management; Janus Henderson Investors; Logos Capital; OrbiMed; Qiming Venture Partners USA; RTW Investments; Surveyor Capital; Third Point; venBio Partners; Vivo Capital; Wellington Management$51M-Ventyx Biosciences is a clinical-stage biotechnology company based in Encinitas, California, developing a pipeline of potent and selective small-molecule immune modulators for inflammatory diseases and autoimmune disorders, including gastrointestinal and dermatological indications. The company combines clinical-stage programs from three prior entities founded by CEO Raju Mohan and New Science Ventures, while leveraging its drug discovery platform for additional preclinical candidates targeting challenging inflammatory targets. In March 2021, Ventyx raised $114 million in an equity financing round led by venBio Partners, with participation from investors including Third Point, RTW Investments, Janus Henderson Investors, Wellington Management, OrbiMed, Surveyor Capital (a Citadel company), Farallon Capital, Vivo Capital, Logos Capital, Qiming Venture Partners USA, Cormorant Asset Management, and founding investor New Science Ventures. Richard Gaster and Aaron Royston from venBio Partners, along with Jigar Choksey from Third Point, joined the board in connection with the financing. Proceeds were allocated to accelerate clinical development of immunology programs and advance preclinical efforts using the company's drug discovery engine.
Mar-21Series AvenBio Partners$114M-Ventyx Biosciences, a clinical-stage biotechnology company founded in 2019 and headquartered in Encinitas, California, focuses on developing a pipeline of immune modulators for inflammatory diseases and autoimmune disorders. The company combines clinical-stage programs from three entities founded by Raju Mohan and New Science Ventures, along with preclinical programs targeting high-value immunology targets. In March 2021, Ventyx raised $114 million in an equity financing round led by venBio Partners, with participation from investors including Third Point, RTW Investments, Janus Henderson Investors, Wellington Management, OrbiMed, Surveyor Capital, Farallon Capital, Vivo Capital, Logos Capital, Qiming Venture Partners USA, Cormorant Asset Management, and founding investor New Science Ventures. The funds supported advancement of its diverse immunology pipeline. venBio Partners, a life sciences investment firm, led the round and joined the board with representatives Richard Gaster, Aaron Miri, and Jigar Raythatha. The financing brought together assets into a diversified portfolio of best-in-class clinical and preclinical programs. A subsequent Series B round of $51 million occurred in October 2021. Ventyx later went public and faced challenges, culminating in its acquisition by Eli Lilly in March 2026 at $14.00 per share in an all-cash deal, converting shares and options to cash consideration.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Ventyx Biosciences

When was Ventyx Biosciences founded?Ventyx Biosciences was founded in 2018.
Where is Ventyx Biosciences headquartered?Ventyx Biosciences is headquartered in United States.
How many employees does Ventyx Biosciences have?As of today, Ventyx Biosciences has over 82 employees.
Who is the CEO of Ventyx Biosciences?Ventyx Biosciences' CEO is Raju S. Mohan.
Is Ventyx Biosciences publicly listed?Yes, Ventyx Biosciences is a public company listed on Nasdaq.
What is the stock symbol of Ventyx Biosciences?Ventyx Biosciences trades under VTYX ticker.
When did Ventyx Biosciences go public?Ventyx Biosciences went public in 2021.
Who are competitors of Ventyx Biosciences?Ventyx Biosciences main competitors include Guizhou Sanli, Inventiva, Absci, Collegium Pharmaceutical, CStone Pharmaceuticals, Corvus Pharma, China TCM, ACROBiosystems, Xeris Biopharma, Strides Pharma.
What is the current market cap of Ventyx Biosciences?Ventyx Biosciences' current market cap is $1B.
Is Ventyx Biosciences profitable?No, Ventyx Biosciences is not profitable.
How many companies Ventyx Biosciences has acquired to date?Ventyx Biosciences hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Ventyx Biosciences has invested to date?Ventyx Biosciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Ventyx Biosciences

Lists including Ventyx Biosciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial